Home › RLT targets by cancer › Bladder Cancer
Radioligand therapy · Bladder Cancer

Radioligand Therapy Targets in Bladder Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in bladder cancer (including urothelial carcinoma). 4,437 show detectable protein staining. Established and emerging radioligand targets expressed in bladder cancer include HER3 (ERBB3), ITGAV, EGFR and Nectin-4 (NECTIN4). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own bladder cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank bladder cancer targets free

Established and emerging radioligand targets in bladder cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in bladder cancer:

TargetIHC in bladder cancer% positiveInternalizes
HER3 (ERBB3)High (0.83)100%yes
ITGAVHigh (0.82)100%—
EGFRHigh (0.79)100%yes
Nectin-4 (NECTIN4)High (0.67)92%no
c-MET (MET)High (0.64)100%yes
B7-H3 (CD276)High (0.61)100%—
ITGB6High (0.53)67%—
STEAP2High (0.52)100%—
SSTR2Medium (0.47)92%yes
CEA (CEACAM5)Medium (0.44)67%—
FAPMedium (0.37)60%yes
HER2 (ERBB2)Medium (0.33)58%yes
TROP2 (TACSTD2)Medium (0.30)55%uncertain
TMEFF2Medium (0.28)75%—
CAIX (CA9)Low (0.12)27%no
EPCAMLow (0.07)11%—
Mesothelin (MSLN)Low (0.03)8%yes
KITLow (0.03)8%no

Top cell-surface targets for bladder cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in bladder cancer% positiveInternalizesClinical stage
1EGFR
epidermal growth factor receptor
High (0.79)100%yesFDA-Approved
2HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.83)100%yesFDA-Approved
3c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.64)100%yesFDA-Approved
4IGF1R
insulin like growth factor 1 receptor
High (0.73)100%yesFDA-Approved
5S1PR1
sphingosine-1-phosphate receptor 1
High (0.58)82%yesFDA-Approved
6MAOB
monoamine oxidase B
High (0.94)100%—FDA-Approved
7AMFR
autocrine motility factor receptor
High (0.93)100%yesDiscovery
8NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.79)100%uncertainFDA-Approved
9LSR
lipolysis stimulated lipoprotein receptor
High (0.89)100%yesDiscovery
10FZD6
frizzled class receptor 6
High (0.88)100%yesDiscovery
11HRH4
histamine receptor H4
High (0.70)100%yesClinical
12NOTCH1
notch receptor 1
High (0.64)100%yesClinical
13IL1R2
interleukin 1 receptor type 2
High (0.64)100%yesDiscovery
14FZD3
frizzled class receptor 3
High (0.81)100%yesDiscovery
15GPR139
G protein-coupled receptor 139
High (0.82)100%yesDiscovery
16MST1R
macrophage stimulating 1 receptor
High (0.52)100%yesFDA-Approved
17ADRM1
ADRM1 26S proteasome ubiquitin receptor
High (0.85)100%uncertainFDA-Approved
18FAAH
fatty acid amide hydrolase
High (0.78)100%—FDA-Approved
19CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.64)91%yesClinical
20FGFR1
fibroblast growth factor receptor 1
Medium (0.48)91%yesFDA-Approved
21NOTCH3
notch receptor 3
High (0.56)100%yesClinical
22TNFRSF1A
TNF receptor superfamily member 1A
High (0.58)100%yesClinical
23SSTR2
somatostatin receptor 2
Medium (0.47)92%yesFDA-Approved
24KCNG1
potassium voltage-gated channel modifier subfamily G member 1
High (0.73)100%—FDA-Approved
25TREM1
triggering receptor expressed on myeloid cells 1
High (0.72)92%uncertainClinical

Internalizing receptors in bladder cancer

Targets expressed in bladder cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

EGFR · HER3 (ERBB3) · c-MET (MET) · IGF1R · S1PR1 · AMFR · LSR · FZD6 · HRH4 · NOTCH1 · IL1R2 · FZD3

Bladder Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in bladder cancer. Clinical precedent lowers development risk but usually means more competition:

EGFR · HER3 (ERBB3) · c-MET (MET) · IGF1R · S1PR1 · MAOB · NR3C2 · HRH4 · NOTCH1 · MST1R · ADRM1 · FAAH

How these bladder cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in bladder cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank bladder cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free bladder cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist bladder cancer targets for your program · 5 free analyses, no card Rank bladder cancer targets free